Latest news with #AmericanCancerSociety
News18
a day ago
- Health
- News18
Best Cancer Screening Tests For Women In 2025
Breast cancer screening holds the power to transform outcomes dramatically. While international guidelines provide a strong foundation, local adaptation is essential. Breast cancer continues to be the most commonly diagnosed cancer among women in India, surpassing cervical cancer over the past decade. Global guidelines now emphasize risk-based screening over one- size-fits-all approaches. This includes taking family history, genetics, menstrual and reproductive history, lifestyle, and breast density into account. With increasing awareness, evolving technologies, and more robust global and Indian data, 2025 marks a pivotal year in how we think about breast cancer screening. Dr Karishma Kirti, Consultant Breast Specialist and Oncoplastic Surgeon shares all you need to know: International bodies such as the American Cancer Society (ACS) and the U.S. Preventive Services Task Force (USPSTF) now recommend: 1. Mammography beginning at age 40 for average-risk women 2. Annual or biennial mammograms depending on individual risk and access 3. 3D digital mammography (tomosynthesis) for improved detection where available 4. Earlier screening from age 30–35 for high-risk individuals (e.g. BRCA1/2 mutation carriers) India's breast cancer landscape is distinct as a significant proportion of cases are seen in women under 50, late-stage presentation is more common, especially in public hospitals and mammography access remains uneven, particularly outside major cities. One of the most important contributions to global breast cancer screening evidence actually comes from India itself. The Mumbai cluster randomized controlled trial, followed nearly 150,000 women over 20 years. It demonstrated that biennial clinical breast examination (CBE) by trained female health workers led to a significant stage shift to earlier detection. Among women aged 50 and above, there was a 15% reduction in breast cancer mortality. CBE was found to be low-cost, acceptable, and scalable. (Mittra I, et al. Lancet Oncol. 2021;22(3):402–15.) This study offers conclusive, real-world evidence that CBE, when done systematically with proper follow- up, saves lives especially in low- and middle-income countries (LMICs) like India. What about breast self-examination? While breast self-exams are no longer formally recommended for screening in the West, breast awareness knowing what's normal for you is still vital in India. Encouraging monthly self-checks and timely reporting of lumps or changes can lead to earlier diagnosis. Many women first discover their cancer themselves, not through screening, but by noticing a lump or change. In the absence of national guidelines, these are some of the recommendations I use in my clinic to guide my patients through screening for breast cancer. This tiered, risk-based approach is based on both the evidence and the ground realities of healthcare access in India. Breast cancer screening holds the power to transform outcomes dramatically. While international guidelines provide a strong foundation, local adaptation is essential. For Indian women, the best approach combines: Early vigilance, Accessible technology, and Open conversations around breast health. The earlier we detect, the more lives we save. The News18 Lifestyle section brings you the latest on health, fashion, travel, food, and culture — with wellness tips, celebrity style, travel inspiration, and recipes. Also Download the News18 App to stay updated! view comments Location : New Delhi, India, India First Published: July 22, 2025, 19:23 IST News lifestyle » health-and-fitness Best Cancer Screening Tests For Women In 2025 Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
Yahoo
2 days ago
- Business
- Yahoo
Betting Big on Cancer: 3 Oncology Stocks Set to Surge in 2025
An updated edition of the June 10, 2025, article. The global cancer treatment market is experiencing rapid growth, driven by rising cancer incidence, aging population and increasing demand for safer, more effective therapies. Per the American Cancer Society, in the United States alone, over 2 million new cancer cases and 618,000 related deaths are projected for 2025. Breakthroughs in immunotherapy, targeted treatments, and personalized cancer vaccines are reshaping the oncology landscape. These next-generation therapies offer greater precision and improved outcomes, supporting strong market expansion. Major pharma companies — including Novartis NVS, AstraZeneca AZN, Johnson & Johnson JNJ, Pfizer PFE, AbbVie ABBV, Bristol Myers Squibb and Eli Lilly LLY — are investing heavily in cutting-edge approaches like antibody-drug conjugates (ADCs) and immuno-oncology agents. Meanwhile, smaller biotechs are driving innovation, making them attractive acquisition targets for larger players seeking to enhance their oncology pipelines. As scientific progress accelerates, the oncology market is poised for robust, long-term growth — offering compelling opportunities for investors. These factors highlight the huge potential of cancer-focused companies. With our thematic screens, you can easily spot stocks tied to trends shaping the future of investing. If the cancer space appeals to you and you're looking to align your portfolio with this rising trend, now might be the time to consider stocks like J&J, Novartis and Allogene Therapeutics ALLO 3 Cancer Stocks in Focus J&J's Oncology segment comprises around 27% of its total revenues. Its oncology sales rose 22.3% on an operational basis in the second quarter of 2025 to $6.3 billion, driven by strong market growth and share gains of key products such as multiple myeloma treatment Darzalex and prostate cancer drug, Erleada. New cancer drugs, such as Carvykti, Tecvayli, Talvey and Rybrevant plus Lazcluze, contributed significantly to growth as they witnessed strong launches. On its second-quarter conference call, J&J stated that it expects its oncology sales to reach $50 billion by the end of the decade. J&J seems quite confident in the target, citing strong growth in its marketed cancer drugs and the potential of upcoming launches like TAR-200 in bladder cancer and the subcutaneous formulation of Rybrevant plus Lazcluze for advanced EGFR-mutated non-small cell lung cancer (NSCLC). TAR-200 is under priority review with the FDA for treating non-muscle invasive bladder cancer and is expected to be approved this year. The subcutaneous formulation of Rybrevant plus Lazcluze has been recommended for approval in the EU while it is under review in the United States. J&J's oncology pipeline has gained strong momentum in the last year and a half, with promising developments in colorectal and head and neck cancers. In this period, J&J had eight proof-of-concept readouts, which led the candidates to move to late-stage pivotal studies across the portfolio. J&J has a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Novartis has a diverse oncology portfolio, including targeted therapies and immunotherapies. The FDA's approval of Kisqali, its CDK4/6 inhibitor for the first-line treatment of postmenopausal women with HR+/HER2 advanced or metastatic breast cancer, significantly boosted the company's oncology portfolio, with the drug now being one of the top growth drivers for the company. In particular, Kisqali has shown robust uptake in the metastatic breast cancer setting. The recent approval of a broader label for Kisqali in the United States and the EU should further fuel its sales. Kisqali recorded sales of $1.1 billion in the second quarter of 2025, up 64% year over year. Other new oncology drugs like Pluvicto (PSMA-positive metastatic castration-resistant prostate cancer) and Scemblix (chronic myeloid leukemia) also put up a stellar performance, setting the momentum for the coming years as well. Novartis' oncology sales rose 20% in constant currency terms to $4.3 billion in the second quarter of 2025. In 2024, Novartis acquired Mariana Oncology and Germany-based MorphoSys AG, which strengthened its oncology pipeline. This Zacks Rank #2 company is also investing in research to develop treatments for both common and rare cancers, focusing on precision medicine strategies. Allogene Therapeutics is focused on developing allogeneic CAR T therapies for treating cancer, especially hematologic indications with high unmet needs. This Zacks Rank #2 company has multiple pipeline candidates in the clinical stage of development, including CAR T cell product candidates — cemacabtagene ansegedleucel (cema-cel or formerly ALLO-501A) and ALLO-316 for cancer indications. Lead candidate, cema-cel, is being developed as a frontline treatment for patients with large B-cell lymphoma (LBCL). In this regard, the company has initiated the pivotal phase II ALPHA3 study to evaluate cema-cel in patients with first-line LBCL. ALLO-316, the company's first CAR T candidate for solid tumors, is being evaluated in the TRAVERSE study in adults with advanced or metastatic renal cell carcinoma. Data from the study has shown that the therapy-induced early anti-tumor activity with deepening responses over time, especially in heavily pre-treated patients with high CD70 expression. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AstraZeneca PLC (AZN) : Free Stock Analysis Report Novartis AG (NVS) : Free Stock Analysis Report Johnson & Johnson (JNJ) : Free Stock Analysis Report Pfizer Inc. (PFE) : Free Stock Analysis Report Eli Lilly and Company (LLY) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report Allogene Therapeutics, Inc. (ALLO) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Newsweek
5 days ago
- Health
- Newsweek
Seven Questions for Miruna Sasu, Cancer Data and Research Guru
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Data is more important than ever before for health care organizations. In today's techy environment, hospitals and clinics can derive insights from vast patient records to deliver care more safely, effectively and efficiently. But patient data is often unstructured, and insights aren't always easy to glean—especially in specialties like oncology, where care records are particularly long and complex. That's where COTA Healthcare comes in. Its platform pulls data from electronic medical records at hospitals and clinics, cleans and adjudicates the clinical notes and then returns them to the health care organizations for cancer research and drug development purposes. That work has enormous potential, as the American Cancer Society estimates that more than 2 million new cancer cases will be diagnosed in 2025 alone. Despite the wide-ranging impacts, this mission is deeply personal for Miruna Sasu, the president and CEO of COTA Healthcare. Ahead of Newsweek's Women's Global Impact forum, Sasu told Newsweek how her work intertwines with her identity. Miruna Sasu is the president and CEO of COTA Healthcare and will be speaking at Newsweek's Women's Global Impact forum on August 5 in New York City. Miruna Sasu is the president and CEO of COTA Healthcare and will be speaking at Newsweek's Women's Global Impact forum on August 5 in New York City. Newsweek Illustration/Canva Newsweek: Walk me through your career trajectory. What sparked your interest in science / health care? Do you recall any formative experiences or mentors? Sasu: "The fight against cancer is personal for me. When I first moved to the U.S., my grandfather was diagnosed with Stage 4 lung cancer. Enrolling him in a clinical trial saved his life and gave us 35 more years with him. That time changed the course of my life. It allowed me to pursue my education and career, and it's a big part of why I do this work. The path to my current role has taken a few turns. I started in food safety with the federal government, then moved into life sciences at Bristol Myers Squibb, where I first worked with real-world data. I continued that work at Johnson & Johnson, focusing on making clinical trials more efficient. Eventually, I felt a strong pull to work entirely in cancer, which brought me to COTA. Along the way, I have been fortunate to have mentors who offered their time, insight and belief in me. Some of them recognized my leadership potential before I was ready to see it in myself. That kind of support shaped who I am and how I lead. It taught me to stay curious, to act with courage and to lead with empathy and purpose." What challenges did you face along the way, and what accomplishments are you most proud of? "There have been plenty of challenges. Change is hard, especially in health care. Most people care deeply about making a meaningful impact on patient outcomes, but org structures don't always make it easy. A lot of my work has focused on getting people aligned across departments and functions and on building trust so we can move forward together." What problems do you aim to solve in your current role? How do you measure progress toward your goals? "We are trying to solve a core problem in health care: how to use data to improve outcomes for patients. It's about making data not just available but actionable. We want to help pharma find the right patients for trials faster, support providers with better insights and ultimately help people get the care they need sooner." What are some recent projects or advancements that you're particularly excited about? "One of the most exciting developments at COTA is the launch of CAILIN, a new suite of AI-powered cancer data tools. For a long time, working with real-world data has required deep technical expertise and significant time to extract insights. CAILIN changes that by allowing users to ask complex research questions in plain language and receive answers within seconds. It also supports our medical abstractors by guiding them through the data curation process more efficiently, which helps improve both speed and quality. We are already seeing the impact of CAILIN across our work. Researchers, clinicians and life sciences teams can now access the insights they need without relying solely on data scientists. This kind of access accelerates decision-making and makes it easier for more people to work directly with high-quality oncology data. CAILIN is not a replacement for human expertise, but it is a powerful tool that helps us do more, faster. It is a meaningful step forward in cancer research, and I am incredibly proud of the team that made it possible." What are you most passionate about? Does your current role enable you to explore this passion? "I care deeply about using data to solve real-world problems. My passion lies in making health care more equitable, more effective and more humane. I'm also passionate about people. Building a healthy, inclusive team culture where people feel valued and motivated is something I work on just as intentionally as product or strategy. The two go hand in hand." Has being a woman shaped your leadership style and/or the way that you think about your work in the health care industry? "It has. Being a woman in leadership has taught me how to lead with both strength and empathy. I've had to work harder at times to prove myself, and that has made me more aware of how I show up and how I support others. I've learned to listen more, to trust my instincts and to lead with clarity. And I've made it a point to open doors for others wherever I can." Women make up 70% of the global health care workforce but hold just 25% of the industry's leadership positions. What do you make of this gender gap? How might we begin to close it? "It's a real gap, and it reflects long-standing structural issues, not a lack of qualified women. We need to be more intentional about creating pathways to leadership. That includes mentorship, sponsorship, fair hiring practices and making sure women have real opportunities to grow and lead. Representation also matters. When women see others leading at the highest levels, it expands what feels possible. I take that responsibility seriously and try to be the kind of leader I would have looked up to earlier in my own journey and to carve out paths for others to have an opportunity to do the same." Sasu will join Newsweek at this year's inaugural Women's Global Impact forum. The August 5 event, hosted at Newsweek's headquarters in New York City, will bring together some of the world's top female executives and connect them with rising stars across industries and job functions. For more information on the event, please visit the Women's Global Impact homepage.
The Independent
6 days ago
- Health
- The Independent
Gastrointestinal cancer is the fastest-growing early-onset cancer in the US, research shows
A new review has identified a dramatic increase in early-onset gastrointestinal cancers among people under 50 in the US. Colorectal cancer was the most common early-onset gastrointestinal cancer in 2022, with over 20,800 diagnoses. The rise in these cancers is largely attributed to modifiable risk factors, including obesity, poor diet, inactive lifestyles, smoking, and alcohol consumption. The prognosis for early-onset gastrointestinal cancers is similar to or worse than later-onset cases, underscoring the need for improved prevention and early detection. The American Cancer Society now recommends regular colorectal cancer screening from the age of 45, a reduction from the previous age of 50. Dramatic rise in gastrointestinal cancers in people under 50
Daily Mail
6 days ago
- Health
- Daily Mail
Woman, 25, shares symptoms doctors dismissed of deadly cancer
A woman has revealed the two symptoms doctors dismissed of her deadly stage four breast cancer. Savannah Caldwell, 25, from Kentucky, was healthy, active, and cherished time with her loved ones. But when she began experiencing persistent exhaustion and aching bones, she turned to doctors for answers. Physicians initially denied her tests saying she was 'too young for cancer'. But after a lump was found on her chest, they agreed to run further tests, and a biopsy was performed. Days later, she was diagnosed with stage four breast cancer that had spread to her ribs, spine, lungs, and possibly her skull. Doctors gave her just a 32 per cent chance of surviving the next five years. She said: 'I was in complete shock. I remember staring at the floor not knowing what to think, not knowing what was next, that was a big worry. 'I've had to grow up faster in a week than I have in 25 years.' Savannah is just one of the ever-increasing number of women diagnosed with breast cancer before they turn 50, which is now among the fastest growing cancers in the age group alongside colon cancer. Researchers say breast cancer cases among young women are now rising by up to 1.85 per cent per year, with an extra 4,000 women being diagnosed with the cancer annually in the U.S. compared to a decade ago. While breast cancer in women in their 20s is rare, it's not unheard of. About 6.5 out of every 100,000 women in their 20s will receive a breast cancer diagnosis, according to the American Cancer Society They remain puzzled by the surge, especially in healthy, young individuals, though some have pointed to possible environmental triggers or earlier onset of puberty as potential factors. For Savannah, the diagnosis came with devastating physical symptoms. Shortly after learning she had stage four breast cancer, the 25-year-old developed crippling back pain caused by a tumor pressing against her spine. The pain became so severe it made walking and even basic movement difficult. Doctors immediately began an aggressive treatment plan, starting with 12 rounds of chemotherapy. Caldwell has already completed nine and may also undergo immunotherapy and radiation depending on how her body responds. Revealing her story to local news station WSAZ , she said: 'At night, especially when with my kids, whenever we cuddle up... I look over... and I just hope I get to see them grow up. 'Things change minute-by-minute, but for the most part I am being very optimistic. I hope my will to fight can get me through. 'I want to fight, I want to live and I want my story to be a beautiful one no matter how long or short it is.' Savannah said the chemotherapy has gone well so far, but that she has started to lose her hair and has been losing weight rapidly, now being down to 88lb. In an update after her fourth round of chemotherapy in June, she said: 'Between the third and fourth chemo a lot has changed. 'My hair is thinning a lot, just yesterday I noticed it is coming out in clumps. I am still experiencing a lot of back pain, neck pain, [pain] in my ribs. 'Through the night, I wake up very nauseous and almost projectile vomiting and it is harder to eat. I look forward to getting this over with, and getting through.' After the ninth chemotherapy, she said she was 'still not sleeping much' but 'hanging in there'. Doctors have diagnosed her with invasive ductal carcinoma, the most common form of breast cancer and behind about 80 percent of all cases. Her friends have started a fundraiser online to raise money to help cover bills and complications linked to the chemotherapy. On the page, they write: 'Savannah is not going to be able to work for a long time. Please help her fight this beast. 'She'd give the shirt off her back for any stranger she met. Let's come together and help her and her fiance!' Research published earlier this year that analyzed 2.1million cases of early-onset cancer diagnosed between 2010 and 2019 found breast cancer, thyroid cancer and melanoma were the fastest rising among young women. Among young men, colon cancer, testicular cancer and melanoma were the most likely to be diagnosed before someone turned 50 years old. Doctors have also suggested that a trend toward having a first child at a later age could be a possible explanation for the rise in diagnoses.
